127 related articles for article (PubMed ID: 3557738)
1. Oral isosorbide-5-mononitrate: pharmacokinetics and clinical efficacy.
Kanto JH
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):129-35. PubMed ID: 3557738
[TBL] [Abstract][Full Text] [Related]
2. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
Döring G
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
[TBL] [Abstract][Full Text] [Related]
3. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
Kumagae H; Koiwaya Y; Tanaka K
Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
[TBL] [Abstract][Full Text] [Related]
4. [Long-term tolerance and effect of isosorbide-5-mononitrate in comparison to isosorbide dinitrate (ISDN retard) in patients with coronary disease].
Smolarz A; Seeliger S; Glocke M
Med Welt; 1981 Apr; 32(14A):548-53. PubMed ID: 6787385
[No Abstract] [Full Text] [Related]
5. Hemodynamic effects of oral isosorbide-5-mononitrate and dinitrate in ischemic heart failure.
Rabinowitz B; Hod H; Chouraqui P; Rath S; Agranat O; Neufeld HN
Clin Cardiol; 1987 Oct; 10(10):603-8. PubMed ID: 3665218
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
Neuhaus R; Johnen R; Vydra L; Solbach C
Pharmatherapeutica; 1986; 4(8):486-95. PubMed ID: 3086899
[TBL] [Abstract][Full Text] [Related]
7. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
Thadani U
Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
Schaumann W
Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
[TBL] [Abstract][Full Text] [Related]
9. [Long-term therapy with nitrates. Relation between dosage and tolerance effect].
Tauchert M; Jansen W; Metternich M; Osterspey A
Herz; 1984 Jun; 9(3):153-65. PubMed ID: 6430769
[TBL] [Abstract][Full Text] [Related]
10. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
Laufen H; Aumann M; Leitold M
Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
[TBL] [Abstract][Full Text] [Related]
11. Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Morrison RA; Fung HL
J Pharmacol Exp Ther; 1984 Oct; 231(1):124-30. PubMed ID: 6491969
[TBL] [Abstract][Full Text] [Related]
12. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
13. [4 different nitrate preparations with regard to the possible development of tolerance in long-term treatment].
Mertens HM; Ohlmeier H; Mannebach H; Kabelitz K; Gleichmann U
Herz; 1985 Jun; 10(3):172-81. PubMed ID: 3926614
[TBL] [Abstract][Full Text] [Related]
14. Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs.
Cayen MN; Hicks D; Karounis J; Dvornik D
J Pharm Pharmacol; 1983 May; 35(5):312-6. PubMed ID: 6134800
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.
Evers J; Bonn R; Boertz A; Cawello W; Dickmans HA; Weiss M
Klin Wochenschr; 1989 Mar; 67(6):342-8. PubMed ID: 2709744
[TBL] [Abstract][Full Text] [Related]
17. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure.
Elkayam U; Roth A; Mehra A; Ostrzega E; Shotan A; Kulick D; Jamison M; Johnston JV; Rahimtoola SH
Circulation; 1991 Nov; 84(5):2040-8. PubMed ID: 1934379
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
[TBL] [Abstract][Full Text] [Related]
19. [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
Leitold M; Laufen H
Arzneimittelforschung; 1983; 33(8):1117-21. PubMed ID: 6685489
[TBL] [Abstract][Full Text] [Related]
20. [Dose-dependent serum concentration of ISDN and its metabolites following administration of ISDN-retard. Studies under steady-state conditions].
Loew D; Deuster U; Burkhardt H; Rietbrock N
Dtsch Med Wochenschr; 1986 Nov; 111(48):1834-7. PubMed ID: 3536397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
